Long-term testosterone therapy completely prevents prediabetes progression to type 2 diabetes (T2D) in men with hypogonadism while improving glycemia, lipids, and Aging Males’ Symptoms (AMS) score, a new study found. 316 men with prediabetes and total testosterone levels ≤12.1 nmol/L combined with symptoms of hypogonadism were analyzed. 297 men received parenteral testosterone undecanoate (T-group), and 87 men with hypogonadism served as the untreated control group. Metabolic and anthropometric parameters were measured twice yearly for 8 years. Researchers found:

• HbA1c decreased by 0.39 ±0.03% in the T-group and increased by 0.63 ±0.1% in the untreated group.
• In the T-group, 90% achieved normal glucose regulation.
• In the untreated group, 40.2% progressed to T2D.
• Testosterone therapy was also associated with significant improvements in fasting glucose, triglyceride:HDL ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol, LDL, HDL, non-HDL, triglycerides, and AMS scale.